<DOC>
	<DOCNO>NCT02472145</DOCNO>
	<brief_summary>The primary objective study Part A ass safety talacotuzumab ( formerly CSL362 ) monotherapy confirm recommend Phase 2 dose ( RP2D ) participant acute myeloid leukemia ( AML ) experimental therapy appropriate . The primary objective study Part B ass complete response ( CR ) rate overall survival ( OS ) participant AML eligible intense induction chemotherapy randomly assign receive decitabine plus talacotuzumab RP2D decitabine alone .</brief_summary>
	<brief_title>An Efficacy Safety Study Decitabine ( DACOGEN ) Plus Talacotuzumab ( JNJ-56022473 ; Anti CD123 ) Versus Decitabine ( DACOGEN ) Alone Participants With Acute Myeloid Leukemia ( AML ) Ineligible Intensive Chemotherapy</brief_title>
	<detailed_description>This 2-part , open-label , multicenter , Phase 2/3 study conduct participant AML suitable experimental therapy ( Part A ) participant untreated AML eligible intense induction chemotherapy hematopoeitic stem cell transplantation ( HSCT ) ( Part B ) . In Study Part A , safety , pharmacokinetic ( PK ) pharmacodynamic ( PD ) profile assess confirm RP2D 9 milligram per kilogram ( mg/kg ) talacotuzumab . In Study Part B , participant randomize 1:1 ratio either decitabine + talacotuzumab ( arm 1 ) decitabine alone ( arm 2 ) . Blood bone marrow sample do Part A B disease assessment , PK , PD , biomarkers collect participant . Safety monitor throughout study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>De novo secondary acute myeloid leukemia ( AML ) ( post myelodysplastic syndrome [ MDS ] myeloproliferative neoplasm [ MPN ] leukemogenic chemotherapy ) accord WHO 2008 criterion For Part A : Participants With AML : treatment naive relapse experimental therapy appropriate ( assessed treat physician ) For Part B : Greater equal ( &gt; = ) 75 year age &gt; = 65 75 year age least one following : congestive heart failure ejection fraction less equal ( &lt; = ) 50 percent ; creatinine great ( &gt; ) 2 milligram per deciliter ( mg/dL ) ; dialysis prior renal transplant ; document pulmonary disease lung diffuse capacity carbon monoxide ( DLCO ) &lt; = 65 percent expect , forced expiratory volume 1 second ( FEV1 ) &lt; = 65 percent expect dyspnea rest require oxygen ; eastern cooperative oncology group ( ECOG ) performance status 2 ; prior current malignancy require concurrent treatment ; unresolved infection ; comorbidity , Investigator 's opinion , make participant unsuitable intensive chemotherapy must document approve Sponsor randomization Previously untreated AML ( except : emergency leukopheresis and/or hydroxyurea screen phase control hyperleukocytosis must discontinue least one day prior start study therapy ) Not eligible allogeneic hematopoietic stem cell transplantation ECOG Performance Status score 0 , 1 2 A woman must either : Not childbearing potential : postmenopausal ( [ &gt; ] 45 year age amenorrhea least 12 month ; If , childbearing potential must practice highly effective method birth control A woman childbearing potential must negative serum ( betahuman chorionic gonadotropin [ betahCG ] ) urine pregnancy test screen A man sexually active woman childbearing potential vasectomy must agree use barrier method birth control eg , either condom spermicidal foam/gel/film/cream/suppository partner occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository least 3 month last study treatment Acute promyelocytic leukemia ( 15 ; 17 ) , molecular equivalent ( PMLRARalpha ) For Part B : Known leukemic involvement clinical symptom leukemic involvement central nervous system Participants receive prior treatment hypomethylating agent For Part A : Participants recover clinically significant toxicity ( exclude alopecia hematologic toxicity ) previous surgery , radiotherapy , target therapy , chemotherapy less equal Grade 1 Any uncontrolled active systemic infection require treatment intravenous ( IV ) antibiotics A history human immunodeficiency virus ( HIV ) antibody positive test positive HIV test screen Active systemic hepatitis infection require treatment clinically active liver disease</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia , myeloid , acute</keyword>
	<keyword>DACOGEN</keyword>
	<keyword>Decitabine</keyword>
	<keyword>JNJ-56022473</keyword>
	<keyword>CLS362</keyword>
</DOC>